Skip to content
Operation Infinite Justice – Lifestyle
Author:
NOVO NORDISK INC.
Novo’s Ozempic® (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events (death, heart attack, and stroke) in adults with type 2 diabetes compared to switching to Mounjaro® (tirzepatide), in real-world analysis at EASD
September 29, 2026
Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596
September 29, 2026
Novo’s denecimig demonstrates tolerability after switch from emicizumab in FRONTIER5 study of people with hemophilia A as published in the Journal of Thrombosis and Haemostasis
September 17, 2026
New Copenhagen facility to strengthen Europe’s quantum manufacturing capabilities
September 4, 2026
Novo Nordisk’s Awiqli®, the first once-weekly basal insulin for adults with type 2 diabetes, now available in the US
August 11, 2026
Novo Nordisk takes action to stop multiple misleading national GLP-1 advertising campaigns by Eli Lilly
July 21, 2026
Novo Nordisk’s denecimig (Mim8) demonstrated positive results in long term safety and efficacy in phase 3 hemophilia A FRONTIER extension study at ISTH 2026
July 11, 2026
No easy answers: European research consortia take on major challenges
July 10, 2026
Wegovy® is now accessible to eligible Medicare beneficiaries living with obesity through Medicare GLP-1 Bridge
July 1, 2026
Novo Nordisk to showcase new data across its hemophilia portfolio at the ISTH Congress 2026, featuring investigational denecimig
June 26, 2026
1
2
Next Page
→